Abstract: Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.

Abstract: The invention relates to compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR ? and/or PPAR? agonists.

Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.

Abstract: The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXR? and/or LXR? agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

Abstract: This invention relates to compounds of the formula I: wherein one of R6, R7 and R8 is and R1 to R15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR ? and/or PPAR? agonists.

Abstract: A sealing structure in a fuel cell and/or an electrolyzer (particularly a solid-oxide fuel cell and/or a solid-oxide electrolyzer) is arranged between neighboring separator plates of a cell stack. The sealing structure is constructed in at least two layers, including at least one insulating layer and at least one sealing layer.

Abstract: A fuel cell includes a cathode-electrolyte-anode unit, and a perforated foil structure distributes fuel gas over an electrode surface thereof. Longitudinal axes of at least some of the holes forming perforations in the foil are inclined differently relative to the foil surface such that, near a fuel gas feed, the outlet openings of the holes facing the electrode are oriented at least slightly toward the area of the fuel gas outlet from the fuel cell. Near a fuel gas outlet, the inlet openings of the holes facing the electrode are oriented at least slightly to the area of the fuel gas feed. However, holes whose inlet openings facing away from the electrode are oriented toward the fuel gas feed, and holes whose outlet openings facing away from the electrode are oriented toward the fuel gas outlet, may also be arranged alternately side-by-side.

Abstract: The invention relates to an aqueous pharmaceutical composition containing moxifloxacin and less than 10 ppb iron.

Abstract: A fuel cell stack comprises several mutually stacked fuel cells, each of which has a cathode-electrolyte-anode unit, and a perforated foil for distributing a fuel gas over a first electrode surface. The foil carries the cathode-electrolyte-anode unit and is assembled with a further structure to form an enclosure having a cavity through which fuel gas flows to the first electrode. Opposite the cathode-electrolyte-anode unit, each enclosure has a distribution configuration for distributing air-oxygen over the surface of the second electrode of an adjacent enclosure, so that a cathode-electrolyte-anode unit and a distribution configuration are situated between the foil and the further structure of adjacent enclosures in the stack. In addition, the stack contains at least one bracing enclosure whose walls have an impermeable construction and which is filled with a material expands when heated.

Abstract: Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R8, A, A1 and n have the significance indicated in the specification.

Abstract: This invention relates to compounds of the formula wherein one of R6, R7 and R8 is and X, Y1 to Y4, R1 to R14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: This invention relates to compounds of the formula wherein one of R5, R6 and R7 is and X1, X2, Y1 to Y4, R1 to R13 and m and n are defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: There are presented compounds of the formula wherein R6 and R7 is R4 and R5 or R5 and R6 together with the carbon atoms to which they are attached, form a ring as defined in the description and X1, X2, Y1 to Y4, R1 to R13 and n are as specified in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: This invention relates to compounds of the formula wherein one of R6, R7 or R8 is and all enantiomers and pharmaceutically acceptable salts and/or esters thereof as well as pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: The present invention relates to compounds of formula (I) 1

Abstract: The present invention provides compounds of formula (I) 1

Abstract: This invention relates to compounds of the formula 1

Abstract: A sealing structure in a fuel cell and/or an electrolyzer (particularly a solid-oxide fuel cell and/or a solid-oxide electrolyzer) is arranged between neighboring separator plates of a cell stack. The sealing structure is constructed in at least two layers, including at least one insulating layer and at least one sealing layer.

Abstract: A housing arrangement can be connected to a flywheel for rotation in common around an axis of rotation, and a pressure element is connected to the housing arrangement for rotation in common around the axis of rotation but is able to shift in the axial direction. A release spring arrangement includes at least one spring element which acts on the pressure element and is supported against the flywheel after the housing arrangement has been attached to the flywheel. Each spring element is held in place on the pressure element by means of a fastening element.

Abstract: A method for the production of nanodispersions, in which at least two metered partial streams are brought together in such a way that they are subject to thorough mixing caused by turbulence. The partial streams have a flow rate in the range from 0.1 to 500 ml/h and the mixed stream has an overall flow rate in the range from 1 ml/h to 500 ml/h. The turbulent mixing leads to the formation of a disperse phase in a continuous phase with a dispersity of 0.1 to 5000 nm. Another object of the invention is a method for the in-situ formulation of a pharmaceutical dispersion, with in-line application of the pharmaceutical dispersion.